Updates in the Diagnosis and Management of HER2- Mutant NSCLC
On January 30, 2025, a select group of physicians with expertise in lung cancer from academic and community practices participated in an in-person scientific interchange and workshop to discuss updates in the diagnosis and management of HER2-mutant non-small cell lung cancer (NSCLC). In a discussion led by Joshua Sabari (JS) and Benjamin Levy (BL), perspectives and insights on the challenges in diagnosing and managing HER2-mutated NSCLC, factors that guide treatment and sequencing decisions, and efficacy and safety data from recent key clinical trials were exchanged. Important points from the workshop are outlined below.
Related Content:
